| http://www.w3.org/ns/prov#value | - OLOGYBaxter Adds Recombinant Protein to Specialty Therapeutics Portfoliomarket acceptance of such product; other productdevelopment risks; and other risks identified in the company's most recentfiling on Form 10-Q and other SEC filings all of which are available onthe company's website.
|
